ArticleCurrent medicinal chemistry2026
IL-33 Alleviates Sepsis-Induced Liver Injury by Regulating the NF-κB/BCL-2 Pathway.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-33 (IL-33), a tissue-derived alarmin released during sterile and infectious stress, modulates inflammatory responses in an organ-specific manner. Although IL-33 is implicated in hepatic pathophysiology, its functional mechanism in sepsis-induced liver injury (SILI) remains insufficiently characterized.
methodsSILI was modeled in vivo via cecal ligation and puncture (CLP) and in vitro using lipopolysaccharide (LPS)-stimulated primary hepatocytes. The multimodal evaluations included oxidative stress analysis, inflammatory cytokine measurements, liver functional biomarker analysis, and histomorphological studies. IL-33 signaling was investigated by combining transcriptomic pathway analysis with pharmacological interventions with soluble ST2 decoy receptor (sST2) and ST2-neutralizing (anti-ST2) antibodies. The SILI model dynamically increased the IL-33 level.
resultsExogenous IL-33 conserved liver architecture, improved function, and reduced both inflammation and oxidative damage. Critically, blocking IL-33/ST2 signaling with an anti-ST2 antibody or sST2 eliminated the protective effect of IL-33, worsening hepatocellular damage. Mechanistic investigations revealed that IL-33/ST2 stimulation reduced NF-κB pathway activity, improved BCL-2 expression, and inhibited caspase-3- mediated apoptosis. The lack of the antiapoptotic effects of IL-33 on NF-κB pathway activation validated its regulatory axis specificity. DISCUSSION: This study identifies IL-33/ST2-NF-κB-BCL-2 as a key axis mitigating hepatocyte apoptosis in SILI. IL-33-based therapies may offer dual control of inflammation and cell death, though clinical translation requires temporal optimization.
conclusionOur results suggest that the pharmacologically targeted IL-33/ST2-NF- κB-BCL-2 pathway decreases sepsis-induced hepatocyte apoptosis. These findings indicate that IL-33-based treatments may be feasible for treating SILI and that this axis coordinates cytoprotection by concurrently controlling inflammatory signals and apoptotic processes.
Indexed as
Identifiers
41572767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.